Assembly biosciences initiates phase 1b clinical trial evaluating next generation core inhibitor abi-h3733 for the treatment of chronic hepatitis b virus infection

South san francisco, calif., june 06, 2022 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis b virus (hbv) and other viral diseases, today announced the initiation of a phase 1b trial of its investigational next-generation, highly potent core inhibitor abi-h3733 (3733).
ASMB Ratings Summary
ASMB Quant Ranking